Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on LinkedIn about a paper by Ryan D’Souza et al. published in BMJ Journals:

“Chemotherapy-induced neuropathy is still one of the biggest problems reducing patients’ quality of life!

A global analysis found that approximately 41% of cancer patients undergoing chemotherapy develop chronic painful neuropathy. The study pooled data from 77 studies across 28 countries, including nearly 11,000 patients.

Key Findings:

Platinum-based agents (40.5%) and taxanes (38%) were associated with the highest neuropathy rates.
FOLFOX had the lowest neuropathy prevalence (16.5%).
Lung cancer patients had the highest prevalence (62%), while ovarian cancer (31.5%) and lymphoma (36%) had the lowest.
Asian studies reported the highest neuropathy prevalence (46.5%), while European studies showed the lowest.

The researchers emphasized the urgent need for tailored pain management strategies and further research to understand regional and treatment-related disparities.”

“Global estimates of prevalence of chronic painful neuropathy among patients with chemotherapy-induced peripheral neuropathy: systematic review and meta-analysis of data from 28 countries, 2000–24”

Authors: Ryan D’Souza, Chandan Saini, Nasir Hussain, Saba Javed, Larry Prokop, and Yeng Her.

Elvina Almuradova: Chemotherapy-induced neuropathy is still one of the biggest problems reducing patients’ QOL

More posts featuring Elvina Almuradova.